Ignite Creation Date:
2025-12-24 @ 7:03 PM
Ignite Modification Date:
2026-02-18 @ 12:49 PM
Study NCT ID:
NCT03310957
Status:
COMPLETED
Last Update Posted:
2025-12-12
First Post:
2017-10-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Sponsor:
Seagen Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Triple Negative Breast Neoplasms | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Breast cancer | View |
| None | Breast carcinoma | View |
| None | Triple negative breast cancer | View |
| None | Locally-advanced breast cancer | View |
| None | Metastatic breast cancer | View |
| None | Tumors, breast | View |
| None | Breast tumors | View |
| None | pembrolizumab | View |
| None | LIV-1 protein, human | View |
| None | Ladiratuzumab vedotin | View |
| None | hLIV22-vcMMAE | View |
| None | Seattle Genetics | View |